0001714899-24-000060.txt : 20240215
0001714899-24-000060.hdr.sgml : 20240215
20240215211442
ACCESSION NUMBER: 0001714899-24-000060
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ho Carole
CENTRAL INDEX KEY: 0001724605
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38311
FILM NUMBER: 24645604
MAIL ADDRESS:
STREET 1: C/O DENALI THERAPEUTICS INC.
STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Denali Therapeutics Inc.
CENTRAL INDEX KEY: 0001714899
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 463872213
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 866-8548
MAIL ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
wk-form4_1708049673.xml
FORM 4
X0508
4
2024-02-13
0
0001714899
Denali Therapeutics Inc.
DNLI
0001724605
Ho Carole
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
1
Common Stock
2024-02-13
4
S
0
2784
17.29
D
145010
D
Common Stock
2024-02-14
4
S
0
1405
17.79
D
143605
D
Common Stock
183219
I
See footnote
Common Stock
25000
I
See footnote
Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Includes 129,435 RSUs.
The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.55 to $17.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price
The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
/s/ Tyler Nielsen, by power of attorney
2024-02-15